QKY-613

QKY-613 is a prodrug that enhances immune surveillance by targeting nucleic acid modification pathways. QKY-613 promotes the selective incorporation of 6mdA (N6-methyldeoxyadenosine) into viral DNA, enhancing the phase separation potential of DNA, thereby increasing the activation of cGAS and strengthening host immune surveillance. In virus-infected mouse models, QKY-613 significantly reduced mortality in aged mice. QKY-613 holds promise for research on nucleic acid modification-based immune surveillance mechanisms[1].

Product Specifications

CAS Number

[2646682-38-2]

UNSPSC

12352005

Target

Cyclic GMP-AMP Synthase

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/qky-613.html

Smiles

O[C@H]1C[C@H](N(C=N2)C3=C2C(NC)=NC=N3)O[C@@H]1COP(OC4=CC=CC=C4)(N[C@H](C(OCC5=CC=CC=C5)=O)C)=O

Molecular Formula

C27H31N6O7P

Molecular Weight

582.54

References & Citations

[1]Wang N, et al. Host RNA N6-methyladenosine and incoming DNA N6-methyldeoxyadenosine modifications cooperatively elevate the condensation potential of DNA to activate immune surveillance. Mol Ther. 2024 Dec 4;32 (12) :4418-4434.